Ainos Inc (AIMD) Share Price

I like what I am seeing.
https://finance.yahoo.com/news/ainos-achieves-major-breakthrough-japan-150000331.html

LOL...🥳...

Looks good $1.40s in the horizon I can smell it with that robot sensor

georgie18

Member Level
Re: georgie18 post# 388352

Thursday, January 23, 2025 9:28:06 AM

Post#
388939
of 388960
AIMD...70s adding here...🥳Loading under $1...

georgie18

Member Level
Re: georgie18 post# 670590

Friday, January 10, 2025 1:11:43 PM

Post#
671056
of 672094
AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

AIMD...70s adding here...🥳Loading under $1...

georgie18

Member Level
Re: georgie18 post# 670590

Friday, January 10, 2025 1:11:43 PM

Post#
671056
of 672094
AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

$AMPG Article : AmpliTech Group Inc. (AMPG): This Small-Cap Stock Is Poised To Outperform in 2025

https://finance.yahoo.com/news/amplitech-group-inc-ampg-small-142839733.html

News : Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
https://finance.yahoo.com/news/ainos-granted-180-day-extension-140000423.html

$AIMD a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday environments."
https://finance.yahoo.com/news/ainos-unveils-ai-nose-robotics-150000016.html

$AIMD Key Benefits of Joining the Ainos Alliance:

Leverage Decades of Expertise: Collaborate with a proven leader in AI and sensory technology.

Secure First-Mover Advantage: Integrate AI Nose Technology into your products to capture market share.

Expand Applications: Unlock new possibilities in industrial safety, healthcare, and smart living.

Shape the Future Together: Collaborate on groundbreaking innovations that redefine the capabilities of robots.

"Originated from healthcare use-case, our AI Nose technology represents nearly a decade of innovation and perseverance," said Chun-Hsien (Eddy) Tsai, CEO of Ainos. "With the robotics and humanoid markets experiencing unprecedented growth, this is the moment to act. Partnering with us now means joining a team with a proven track record of success and ensuring your company's position at the forefront of the industry."

To join the Ainos Alliance or learn more about AI Nose, contact us today:

Media and Partnership: info@ainos.com
Investor relation: ir@ainos.com
Website: www.ainos.com

$AIMD AI Nose is a Game-Changer, Elevating Robot's Interaction with Our World

1. Transforming Home Safety

Detects gas leaks, burning odors, and other safety hazards, sending immediate alerts to prevent accidents.

Enhances smart home environments by proactively addressing unpleasant odors, such as those from kitchen waste.

2. Revolutionizing Healthcare

Enables non-invasive early detection of diseases by analyzing volatile organic compounds (VOCs) emitted by you.

Provides real-time health monitoring for chronic disease patients, offering smarter healthcare solutions.

https://finance.yahoo.com/news/ainos-unveils-ai-nose-robotics-150000016.html

AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

AIMD BLOWING UP

AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

AIMD...74s clearing here...🥳

$AIMD Podcast - Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS.
https://drive.google.com/file/d/101N4WNjst-4MEmWe3E_oyCGQiHvbSHDw/view?usp=sharing

$AIMD Podcast - Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS.
https://drive.google.com/file/d/101N4WNjst-4MEmWe3E_oyCGQiHvbSHDw/view?usp=sharing

$AIDM 🔥 Must-Listen Alert! 🔥 Dive into research with @WTR_Research! 🎙️ This podcast discuss #Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, #Sjogren’s Syndrome, and cat FCGS. Don't miss out!
⏳ #AinosInc $AIMD $AIMDW #nasdaq #biotech #Podcast #Research #ListenNow #Sjogren’sSyndrome #Veldona #RareDisease #OrphanDrug https://x.com/WTR_Research/status/1849078364016930937

$AIMD Podcast out, #PharmaPartnerships #DrugOutlicensing #PharmaDeals #SjogrensSyndrome #AutoimmuneDisease #OrphanDrug #RareDisease #ClinicalTrial #AinosInc #AIMD $AIMD #MitsubishiTanabePharma
https://drive.google.com/file/d/1NfmvbVQCrsb6w0ttKZptoQPv_HPKZemL/view?usp=sharing


$AIMD - 1. 🚀 Big news! Ainos, Inc. is partnering with Taiwan Tanabe Seiyaku to introduce VELDONA®️ in Taiwan for Sjögren's syndrome. This condition, affecting 1% globally, causes dry eyes and mouth, with current treatments only managing symptoms. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #DrugOutlicensing #OrphanDrug #PharmaDeals #PharmaPartnerships #RareDisease #SjogrensSyndrome
2. 🌟 Major milestone! The MOU between Ainos and Taiwan Tanabe Seiyaku kickstarts Ainos' Veldona outlicensing strategy. This partnership aims to accelerate the market entry of innovative treatments. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #DrugOutlicensing #OrphanDrug #PharmaDeals #PharmaPartnerships #RareDisease #SjogrensSyndrome
3. 🌍 Promising results! Ainos' VELDONA®️ is showing great potential in clinical trials for Sjögren's syndrome, a condition affecting 1% globally with no curative therapy. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #RareDisease #SjogrensSyndrome

$AIMD News - Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #RareDisease #SjogrensSyndrome
https://www.otcmarkets.com/stock/AIMD/news/story?e&id=3065363

MOU Highlights
1. 🌟 Ainos and Taiwan Tanabe Seiyaku have signed an MOU to advance the manufacturing and Taiwan market promotion of VELDONA®️ for Sjögren’s syndrome. This international cooperation addresses the unmet need for effective treatments and leverages clinical benefits from prior Phase 3 studies. Taiwan Tanabe Seiyaku, a subsidiary of Mitsubishi Tanabe Pharma in Japan, excels in Taiwan and neighboring markets with specialty therapeutics for autoimmune diseases, diabetes, and other major health conditions. #PharmaPartnerships #DrugOutlicensing #PharmaDeals #SjogrensSyndrome #AutoimmuneDisease #OrphanDrug #RareDisease #ClinicalTrial #AinosInc #AIMD $AIMD #MitsubishiTanabePharma

🚀 Exciting Update! 🚀 Ainos has signed an MOU with Taiwan Tanabe Seiyaku Co., Ltd. to advance the production and marketing of Sjögren's syndrome drug, VELDONA, in Taiwan. This international partnership taps into Taiwan Tanabe's strong pharmaceutical expertise and market presence.

New $AIMD Podcast out-
https://drive.google.com/file/d/1sCdlpGCZQSGNObKvzCPsILQtaY9-HmbS/view?usp=sharing

$AIMD News out- Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
https://www.otcmarkets.com/stock/AIMD/news/story?e&id=3062502

Listen to @WTR_Research podcast with @AinosInc to get insight on Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS. A lot to look forward to in 2025!

$AIMD #Veldona #AinosInc

Apple:https://podcasts.apple.com/podcast/id1693448305
Spotify:https://open.spotify.com/show/65HhA2UPZVDW55kA3sCkXh

mix it with reposts of https://x.com/WTR_Research/status/1849078364016930937

Recent podcast, very interesting. 

https://drive.google.com/file/d/1QZCY2SUUD0e7vBbdZMx3CioQynqqCJvu/view?usp=drivesdk

maybe some potential on the long here

$AIMD Tune in to WTR Small-Cap Spotlight with WTR's Do Kim and Jack Lu from
@AinosInc
on Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, Sjogren’s syndrome & cat FCGS
https://x.com/WTR_Research/status/1849078364016930937

There is no cure for Sjogren’s Syndrome, only symptom management. Ainos previous clinical trials show Veldona may improve oral dryness without serious side effects. There is hope for patients

 Sjogren’s syndrome an affect the entire body! In addition to severe dryness, complications can include extreme fatigue, chronic pain, and organ issues. It’s a complex disease!

$AIMD - AINOS Inc.
🔹Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
🔹Taiwan regulatory approval for the trial expected in Q1 2025
🔹Remains committed to a capital-efficient business strategy
🔹Low Float/ OS near 7.6m shares

$AIMD - Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products.
http://www.ainos.com/

Water Tower Research just highlighted the IRB approval for the VELDONA® clinical trial for primary Sjogren's syndrome. This trial, starting in April 2025, could revolutionize treatment for this condition with no approved therapies. https://feeds.issuerdirect.com/news-release.html?newsid=7518957985987465

Exciting news! 🎆 Ainos has received IRB approval for its Sjögren’s Syndrome clinical study at Shuang Ho Hospital, Taipei Medical University! 🌟 Next step: regulatory approvals in Q1 2025. VELDONA has shown promising results in Phase 3 studies. https://feeds.issuerdirect.com/news-release.html?newsid=7333369263066478

Ainos, Inc. is enhancing its patent portfolio with 28 new patents for AI Nose and a groundbreaking nitrogen-oxygen separation technology. This innovation extracts nitrogen and oxygen from air with over 99% purity, using only a third of the energy of traditional methods, revolutionizing energy-efficient medical oxygen supply. https://www.accesswire.com/935576/ainos-expands-patent-portfolio-with-strategic-shareholders-cutting-edge-technology-assets

WTR has just released a recap note on yesterday's Small-Cap Spotlight podcast featuring #AIMD.
https://feeds.issuerdirect.com/news-release.html?newsid=4786114891531438
Here are the key highlights:

Safe, Oral Low-Dose Interferon-a ("IFN-a") Therapeutic
Extensive Clinical History
Rare Disease Focus
Animal Health Potential
Milestones for the Next 18 Months
Don't miss out! If you don't have access to the WTR website, head over to Ainos' IR website under the news section to get all the details. 📈✨

#SmallCapSpotlight #AIMD #Biotech #InvestmentNews #AinosIR #WTRRecap

$AIMD EMA ANALYSIS

$AIMD News Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies https://finance.yahoo.com/news/ainos-advances-healthcare-industrial-innovations-120000322.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

🚨 Let's recap Ainos VELDONA for better pet and human health! Dive into WTR report to discover how #VELDONA is positioned to revolutionize treatments for cat gum disease, #HIV oral warts, and #Sjogren’s syndrome. 🐱💊 #AinosInc $AIMD #AIMD Read more: https://irp.cdn-website.com/7a7a7e3d/files/uploaded/Water_Tower_Research_Management_Series_Report_-_August_26-_2024.pdf

Wash trades are helping no one ....real retail is the only answer , deal trades 10x its actual float and only goes up .06 , come on , get real!!!!

$AIMD Volume up on today's news!!
https://schrts.co/fYFxNiHg

$AIMD News Out!! Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA https://finance.yahoo.com/news/ainos-inc-receives-irb-approval-120000346.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

AIMD................................https://stockcharts.com/h-sc/ui?s=AIMD&p=W&b=5&g=0&id=p86431144783

Don’t blink

$AIMD Technical analysis
https://stockta.com/cgi-bin/analysis.pl?symb=AIMD&mode=table&table=ema

$AIMD Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion

Ainos aims to complete all regulatory approvals for the study in Q4 2024

SAN DIEGO, CA / ACCESSWIRE / September 23, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that it plans to conduct a Taiwan clinical study for very low-dose interferon alpha (VELDONA) on treating Sjögren's syndrome at Taipei Medical University-Shuang Ho Hospital. A total of eight clinical trials have been conducted in the U.S. by the Company to evaluate the use of VELDONA® for treating Sjögren's syndrome. Three Prior Phase 3 studies show positive benefits in increasing unstimulated whole saliva secretion without significant adverse effects.

https://finance.yahoo.com/news/ainos-announced-plan-initiate-taiwan-120000526.html

$AIMD 1 month chart looks oversold? Dip is a gift!!
https://schrts.co/qMPatYRW

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA



Company Update

Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management



The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA® Low-Dose Oral Interferon Formulation as a Potential Treatment for Oral Warts in HIV-Positive Patients





SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (POCT) and low-dose interferon therapeutics, is pleased to announce that its plans to initiate a clinical study for very low-dose interferon alpha (VELDONA) on treating Human immunodeficiency virus (HIV)-related oral warts at the National Taiwan University Hospital. The study aims to evaluate the efficacy of VELDONA®, a low-dose oral interferon-alpha formulation, in treating oral warts in HIV-positive patients undergoing combination antiretroviral therapy. VELDONA® has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for this indication, offering new hope to HIV-positive individuals suffering from oral warts.



------------------------------------------------------------------------------------------------
Overview of the Clinical Study

This clinical study will be conducted by the Infectious Disease Department at National Taiwan University Hospital, one of Taiwan's 25 designated medical centers for HIV management. The hospital oversees nearly 4,000 HIV-positive patients, approximately 11.2% of Taiwan's total HIV cases. The study will enroll 40 participants who will be randomized in a 1:3 ratio to receive either a placebo or VELDONA® in a double-blind trial. Participants will take VELDONA® or a placebo sublingually every day for 24 weeks.

The primary objective of the study is to evaluate the reduction in oral warts' surface area. A successful response is defined as a reduction of 75% or more in the surface area of oral warts compared to baseline, while a non-responsive result indicates less than 75% reduction.

The secondary objectives include evaluating oral wart surface area reduction by 50% or more, as well as participant self-assessments through questionnaires comparing oral health to baseline conditions. The study's Principal Investigator (PI) will also objectively assess the participants' oral conditions.

This clinical study will be conducted in accordance with Good Clinical Practice (GCP) guidelines by Bestat Pharmaservices Corporation, a TFDA-certified Contract Research Organization (CRO). The study is expected to begin in November 2024, with the first patient visit (FPFV) anticipated in November. Patient enrollment is projected to take one year, with the last patient visit (LPLV) expected in May 2026, and study completion anticipated in July 2026. Protocol of the study is currently being reviewed for Investigational Review Board ("IRB") approval by National Taiwan University Hospital and Taiwan Food and Drug Administration (TFDA).



Data from Prior Studies

Ainos has conducted one pilot study and two phase 2 trials in the U.S. involving 77 HIV-positive patients with multiple oral warts. In these trials, patients were randomized to receive either VELDONA® or a placebo, taking the medication three times daily for 24 weeks. After treatment, patients receiving VELDONA® showed significant reductions in oral wart surface area, with decreases of over 75%, and in some cases up to 99%.



Overview of HIV

Human Immunodeficiency Virus (HIV) is the virus responsible for causing AIDS, with two main types: HIV-1 and HIV-2. HIV-1 is the dominant strain worldwide and is the primary cause of AIDS in most countries. HIV-2, found predominantly in West Africa, is less virulent and less likely to progress to AIDS.

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2023, there were approximately 39.9 million people living with HIV worldwide, with 1.3 million new infections and about 630,000 AIDS-related deaths.

In Taiwan, there were around 35,500 individuals living with HIV and 940 reported new cases in 2023. There were 666 new reported cases in August 2024.



Challenges in Treating HIV-Related Oral Warts

Currently, treatment options for HIV-related oral warts are limited, and no established pharmacological therapies exist for this condition. Only a few case reports mention the use of drugs such as cidofovir, bleomycin, cimetidine, podophyllum, or intralesional interferon-alpha injections. Surgical removal is possible but comes with the risk of recurrence.

Ainos believes that VELDONA® has the potential to be a safe and effective treatment for oral warts in HIV-positive individuals, offering a meaningful improvement in their quality of life.

"We are excited by the data we've gathered so far and are optimistic about the potential of VELDONA® to benefit many HIV-positive patients. Oral warts can significantly affect daily activities such as eating and speaking, as well as a person's appearance. We are hopeful that VELDONA® will become an important option for those seeking relief from these symptoms," said Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos
----------------------------------------------------------------------------------------



About Ainos, Inc.

Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.

The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.

Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.




Contact Information

Feifei Shen
ir@ainos.com

SOURCE: Ainos, Inc.



https://www.accesswire.com/918831/ainos-announced-plan-to-initiate-taiwan-clinical-study-for-veldona-as-potential-treatment-of-oral-warts-in-hiv-seropositive-patients-an-orphan-drug-designated-by-the-fda

AIMD new 52 week low

$AIMD Barchart Opinion
https://www.barchart.com/stocks/quotes/AIMD/overview

$AIMD announce that its groundbreaking VELDONA® formulation has been granted an invention patent in Taiwan and has filed for global patent protection under the Patent Cooperation Treaty (PCT). This patent represents a significant milestone in the treatment and prevention of coronavirus infections.

https://finance.yahoo.com/news/ainos-secures-taiwan-invention-patent-123000316.html